-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20th, Eli Lilly and Company announced that its CDK 4/6 inhibitor Weize (Abexili Tablets) will be available nationwide from April 19, 2021, and will continue to be available in many countries.
China issued its first prescription, bringing new treatment options to Chinese patients with advanced breast cancer.
At the same time, in order to help patients with advanced breast cancer reduce the economic burden of medication, the "Ru Ai You Li" charity assistance project initiated by the China Women's Development Foundation and supported by Eli Lilly was officially launched in Beijing, aiming to allow more patients to receive timely treatment.
Breast cancer is the most common cancer among women worldwide.
It is estimated that 90% of breast cancers are diagnosed at an early stage.
Abbasilide is an oral CDK 4/6 inhibitor developed by Eli Lilly.
In December 2020, Abexicil was approved by the National Medical Products Administration (NMPA) of China for HR-positive and HER2-negative locally advanced or metastatic breast cancer, including: 1) Used in combination with aromatase inhibitors Initial endocrine therapy for postmenopausal female patients; 2) Combined with fulvestrant for patients who have experienced disease progression after receiving endocrine therapy.
According to the research data of MONARCH plus released by Eli Lilly in September 2019, Abexicil has achieved good effects in breast cancer patients in China.
The approval of Abexicil in China has brought new treatment options for breast cancer patients.